Arbutus Biopharma Files 8-K with Operational Updates

Ticker: ABUS · Form: 8-K · Filed: 2024-08-01T00:00:00.000Z

Sentiment: neutral

Topics: corporate-actions, financial-reporting

TL;DR

Arbutus Biopharma filed an 8-K on Aug 1, 2024, updating operations and financials. Formerly Tekmira.

AI Summary

Arbutus Biopharma Corporation filed an 8-K on August 1, 2024, reporting on results of operations, other events, and financial statements. The filing also notes the company's former name was Tekmira Pharmaceuticals Corp, with name changes occurring on June 7, 2011, and October 3, 2008. The principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania.

Why It Matters

This 8-K filing provides essential updates on Arbutus Biopharma's operational and financial status, which are crucial for investors to assess the company's current performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is to report on the results of operations and financial condition, other events, and financial statements and exhibits of Arbutus Biopharma Corporation.

When was Arbutus Biopharma Corporation's most recent name change?

The company's name was changed from Tekmira Pharmaceuticals Corp on June 7, 2011.

What was the company's previous name before the 2011 name change?

The company was formerly known as Tekmira Pharmaceuticals Corp, with an earlier name change also recorded on October 3, 2008.

Where are Arbutus Biopharma Corporation's principal executive offices located?

The principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania, 18974.

What is the SIC code for Arbutus Biopharma Corporation?

The Standard Industrial Classification (SIC) code for Arbutus Biopharma Corporation is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001171843-24-004324.txt : 20240801 0001171843-24-004324.hdr.sgml : 20240801 20240801073117 ACCESSION NUMBER: 0001171843-24-004324 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20240801 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 241164291 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_080124.htm FORM 8-K Form 8-K 0001447028 False 0001447028 2024-08-01 2024-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  August 1, 2024 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 2.02. Results of Operations and Financial Condition. On August 1, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. Item 8.01. Other Events. On August 1, 2024, the Company posted an updated corporate presentati

View on Read The Filing